Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the potential of Harrow's BYQLOVI for Post-Operative Ocular Inflammation/Pain and OKYO Pharma's Urcosimod for Neuropathic Corneal Pain

Ticker(s): HROW, OKYO, Formosa Pharmacueticals

Who's the expert?

Institution: Baylor Scott & White Health

Doctor of Optometry at Baylor Scott and White Medical Center in Dallas, TX
Manages over 60 patients a month for ocualr inflammation and pain

Interview Goal

This conversation will focus on the treatment landscape for post op inflammation/pain following ocular surgery. We will also get a physician opinion on the potential of Byqlovi, which is expected to be available in late 2025, and OKYO's urcosimod, currently in Phase 2 clinical trials for neuropathic corneal pain.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.